Kornimate/medical-research-clean huggingface dataset:
outcomes of a game-based educational intervention: healthy kids

Conditions: Obesity and Overweight; Child Health; Physical Activity

Summary: 235 / 5.000 investigators aimed to reduce the risk of obesity by trying a new intervention method that is role-play based, interactive and fun with age-appropriate play materials, considering that learning through play is more efficient.

it was aimed to reduce the risk of obesity by trying a new intervention method based on role-play, interactive and fun with age-appropriate game materials, considering that learning through play is more efficient. two schools were determined as control and intervention groups. an 8-week interactive-game-based intervention program will be applied to children in the intervention group who are at risk for obesity. the program was shaped by a physician-dietician-psychologist and a professional theater actor. family nutrition and physical activity (fnpa) score, food index (fi) score and bmi will be grouped for each child and a risk score will be calculated based on the total score they receive. it will be checked whether there is a decrease in this score after the training.

Eligibility criteria:
inclusion criteria: * all participants who do not meet the criteria of whether or not they agree to participate in the study will be included in the study. exclusion criteria: * neurodevelopmental delays * metabolic disorders potentially leading to obesity * physical disabilities * those whose parents or guardians declined participation.

Keywords: educational intervention prevention of obesity
hormonal monitoring and progesterone adjustment in frozen embryo transfer cycles

Conditions: Female Infertility

Summary: hormonal monitoring impact on overall pregnancy rate in frozen embryo transfer (fet)cycles and hence progesterone supplement adjustments remain debatable in current literature. this prospective randomized study aims to investigate the effect of monitoring and follow-up of serum progesterone, estradiol \& luteinizing hormone (lh) levels and progesterone supplement adjustments on pregnancy outcomes for fet in programmed hormonal replacement therapy cycles in comparison with ultrasound only in control group

progesterone (p4) is a steroidal hormone that is required for successful embryo implantation and maintenance of the pregnancy in natural cycles, fresh in vitro fertilization cycles, and frozen embryo transfer (fet) cycles. women undergoing fet in programmed cycle are unable to provide adequate endogenous p4 and require progesterone supplementation to initiate and maintain the secretory endometrium and pregnancy. there has been previous research into luteal phase support in frozen cycles, which has demonstrated that supplementation of progesterone does impact outcome in fet. despite this evidence for the role of progesterone, there is surprisingly little data on the optimal values for serum p4 during the luteal phase and specifically on the day of embryo transfer in frozen cycles. following years of a prevalent belief that the higher values of p4 are better, it seems that there may be an optimal window for p4 values during the luteal phase in bovine ivf. though progesterone levels on the day of transfer have not yet been studied extensively in humans, tailoring the time of transferring a frozen embryo based on serial p4 values rather than cycle day number alone results in higher pregnancy rates. by direct action on the endometrium, a rise of lh might interfere with endometrial receptivity during a fet cycle, in which no pituitary suppression is used. the significance of lh level on the day before addition of progesterone is not yet well defined. the aim of this study is to investigate the effect of monitoring and follow-up of serum progesterone, estradiol \& luteinizing hormone levels on day of embryo transfer on pregnancy outcomes for fet in programmed hrt cycles in comparison with ultrasound only in control group and to evaluate the effect of progesterone supplements adjustments depending on serum progesterone levels on day of fet in affecting clinical pregnancy rate.

Eligibility criteria:
inclusion criteria: 1. age of female patient 42 years or less 2. normal uterine cavity 3. all embryos are day 5 or day 6 frozen blastocysts exclusion criteria: 1. history of recurrent implantation failure 2. previously known major thrombophilia factors 3. non-compliance to given protocol 4. endometrial thickness \< 7mm after 13 days of priming with estradiol valerate 5. pre-existing metabolic diseases (diabetes mellitus \& hypertension).

Keywords: hormonal monitoring; frozen embryos; progesterone; estradiol
early childhood prevention of childhood overweight

Conditions: Overweight

Summary: you are invited to participate in a research study to understand more about childhood obesity and how to prevent it. we hope to learn how families influence each others eating habits.

this study aims to understand more about childhood obesity and how to prevent it. two different methods of prevention will be tested and participants will be allocated at random to one of these methods. the investigators hope to learn how families influence each others eating habits. participants in this study will attend a series of five classes, once a week for five weeks, on the topic of child feeding. the aim of the classes is to learn how to feed your child so as to prevent future eating and weight problems. the research component includes filling out some surveys before classes begin and at the end of the last class. classes are small and interactive so that parents have a chance to voice concerns and get feedback.

Eligibility criteria:
inclusion criteria: * one or both parents with bmi \> or = to 27.5 * healthy child ages 2-4 years exclusion criteria. - inadequate understanding of the english language
follow-up of sollentuna prevention program

Conditions: Cardiovascular Diseases

Summary: to evaluate long-term effects of one individual- and population-oriented cardiovascular prevention programs in primary care.

in sweden there are unique opportunities to create a relevant comparison group for this study, which is of great importance to the value of this cohort study. of the three study populations two (2-3)will be created by using national registries. 1. the screened group consists of the individuals (n = 5938) who had direct contact with the prevention program, ie undergone a voluntary opportunistic cardiovascular screening (questionnaire, physical examination and testing in connection with visits to health centers) and the rest of all individuals who lived in sollentuna municipality between 1988-1993. 2. relatives of individuals included in the screened group who lived in stockholm county at the time of the intervention will be identified by the use of the medical birth register and the multi-generation register. family members are defined as parents, siblings and children and husband / wife to those in thescreened group and will be analyzed in the same way as those who participated in the intervention for risk of developing cardiovascular disease and cancer. 3. the comparison group consists of the entire population of stockholm county minus sollentuna 1988-93, taking into account population changes (migration, birth, death) during the period. this three populations will be followed-up in national registries and databases all subjects will be monitored for example disease history, socio-economics and biochemical risk factors presented below national registries and research databases. when all the matches of national registers and a local register (amoris)have been done the database will de-identified and anonymized data to be available for statistical processing.

Eligibility criteria:
inclusion criteria in the risk intervention group: * individuals 15 years of age or more who visited three (four) health care centres in sollentuna 1988-1993 were offered to participate in the prevention program exclusion criteria in the screened intervention group: * age \< 15 years

Keywords: prevention cardiovascular disease risk factors
a study of v503, a 9-valent human papillomavirus (9vhpv) vaccine in females 12-26 years of age who have previously received gardasil™ (v503-006)

Conditions: Cervical Cancers; Vulvar Cancers; Vaginal Cancers; Genital Warts

Summary: this study will evaluate whether v503 (9vhpv vaccine), is well tolerated in girls and women between 12 and 26 years old who have previously been vaccinated with gardasil™. participants will receive vaccination with 9vhpv vaccine or placebo on day 1, month 2, and month 6 of the base study. participants who receive placebo in the base study will be eligible to receive vaccination with 9vhpv vaccine on day 1, month 2, and month 6 of the extension study.


Eligibility criteria:
inclusion criteria: participants age 12 to 15 years: * participant is in good health * parent/legal guardian and participant agree to provide study personnel with a primary telephone number for follow-up * participant received a 3-dose regimen of marketed gardasil™ within a 1 year period and the last dose of gardasil™ was at least 1 year from study day 1 * participant has not received any other hpv vaccine * participant is not yet sexually active participants age 16 to 26 years: * participant is in good health * participant agrees to provide a primary telephone number for follow-up * participant received a 3-dose regimen of marketed gardasil™ within a 1 year period and the last dose of gardasil™ was at least 1 year from study day 1 * participant has not received any other hpv vaccine * participant has never had papanicolaou (pap) testing or has only had normal results * participant has a history of 0 to 4 lifetime sexual partners at enrollment exclusion criteria: all participants: * participant has a history of severe allergic reaction that required medical intervention * participant has any disorder that would contraindicate intramuscular injections * participant is pregnant * participant is immunocompromised or has an autoimmune condition * participant has had a splenectomy * participant has received any immune globulin product or blood-derived product * participant has participated in a hpv vaccine clinical trial participants age 16 to 26 only: * participant expects to donate eggs during the study * participant has a history of abnormal cervical biopsy result * participant has a history of hpv-related external genital lesions, external genital cancer, hpv-related vaginal lesions, or vaginal cancer

Keywords: cervical cancer genital warts human papillomavirus vaccine gardasil™
multisite inventory of neonatal-perinatal interventions (mini) minimum dataset

Conditions: Infant, Extremely Premature; Obstetric Labor, Premature; Premature Birth; Intensive Care, Neonatal; Intensive Care Units, Neonatal

Summary: the goal of the tiny baby collaborative multicenter inventory of neonatal-perinatal interventions (mini) minimum dataset is to serve as a registry detailing the outcomes and practices for all deliveries and infants admitted to intensive care at 22-23 weeks' gestation at participating hospitals.

the minimum dataset collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. the data collected include information on: * demographics of mother and infant * mother's health, labor and delivery * infant's health, medical interventions, and clinical outcomes these data are used to: provide participating hospitals with reporting for use in quality improvement; evaluate associations between baseline characteristics, treatments, and outcomes; and track trends in disease and therapy.

Eligibility criteria:
inclusion criteria: * all local births with gestational ages of 22 weeks 0 days - 23 weeks 6 days, regardless of pregnancy outcome or neonatal intensive care (nicu) admission; and * all outborn nicu admissions with gestational age at birth of 22 weeks 0 days - 23 weeks 6 days * optional: centers who desire to include data for nicu admissions of infants born \<22 weeks' gestation may also submit these data.
a study of the safety and tolerability of asp0777 in subjects with alzheimer's disease (ad) taking a stable dose of donepezil

Conditions: Alzheimer's Disease

Summary: this study is intended to determine the safety and tolerability of asp0777 in subjects with alzheimer's disease (ad) taking a stable dose of donepezil.


Eligibility criteria:
inclusion criteria: * subject has a mini-mental status exam score of 18-26 * subject has a diagnosis of "probable" alzheimer's disease * subject has used donepezil for at least 3 months and has been on a stable dose for at least 6 weeks prior to screening * subject has a reliable adult who is residing with him/her during the outpatient portion of the study * subject is medically stable * subject has adequate cognitive, hearing, vision, and language skills * subject is able to ingest oral tablets exclusion criteria: * subject has received any investigational product in another clinical study or post-marketing clinical study within past 3 months * subject has any clinically significant abnormal laboratory tests * subject is a female who is pregnant, lactating or of childbearing potential who refuses to use a form of contraception during the study * subject has a history of a drug allergy or intolerance to memantine or a related compound * subject is currently using anti-dementia drugs (except for donepezil) or has used any such drugs within the last 4 weeks * subject has a score of 2 on item 16 of cornell scale for depression in dementia (csdd) or has an overall csdd score \> 10 * subject is using off-label medicines, non-medicinal compounds, or dietary aids/food supplements to improve cognition that have not been at a stable dose for at least 4 weeks prior to screening and/or are anticipated to change dosing regimen during the study * subject has a history of drug or alcohol abuse within the past 12 months or subject consumes \> 1 drink of alcohol daily, or is unable to refrain from alcohol during the study * subject is a current smoker or recently quit smoking (within the past 12 months) * subject has a clinically significant medical condition that is unstable or is likely to become unstable during the course of the study * subject has history of seizures, other than febrile seizures during infancy * subject has history of repeated falls within past 6 months * subject has a major psychiatric illness or has received treatment for symptoms of a major psychiatric illness within past 1 year. mild psychiatric disorders are allowable

Keywords: asp0777 alzheimer's disease
clinical features and risk factors associated with worse outcome in patients hospitalized for covid-19 pneumonia

Conditions: Covid-19

Summary: the aim of the research is to improve patient management by rapidly identifying, based on the terrain and clinical and biological characteristics, those patients likely to present a severe form of ards at risk of leading to intensive care


Eligibility criteria:
inclusion criteria: * major patient (≥18 years of age) * admitted in march 2020 for confirmed covid-19 lung disease (nasopharyngeal smear or sputum with sars-cov-2 positive pcr). exclusion criteria: * patient who has expressed opposition to participation in the study. * mild forms of infection that do not require hospitalization, * subject under safeguard of justice * subject under guardianship or trusteeship

Keywords: covid_19 sars-cov-2 ards risk factors infection
prehospital emergency care of obstructive respiratory emergencies with the use of teleconsultation

Conditions: Asthma; COPD

Summary: the aim of the study is to investigate the quality of prehospital emergency care in acute respiratory emergencies, when paramedics are supported telemedically by an ems physician.

six ambulances from five different emergency medical service (ems) districts are equipped with a portable telemedicine system. in cases of acute obstructive, respiratory emergencies the paramedics can use this system to contact a so called "tele-ems physician" after consent of the patient was obtained. the tele-ems physician has an audio-connection to the ems team and receives vital parameters (e.g., ecg, pulse oximetry, non-invasive blood pressure) in real-time. the transmission of still pictures (taken with a smartphone), 12-lead-ecgs and video streaming from the inside of the ambulance can also be carried out, if indicated. the tele-ems physician supports the ems team in obtaining all relevant medical history, diagnosis and can delegate the application of medications. this can be carried out to bridge the time to the arrival of an ems physician or in less severe cases without an ems physician on-scene. the quality of prehospital care and the possible influences on the initial inhospital phase should be investigated and compared with regular ems.

Eligibility criteria:
inclusion criteria: * obstructive, respiratory emergency * verbal consent for teleconsultation obtained or patient is not able to consent due the severity of the emergency exclusion criteria: * no respiratory emergency * refused consent for teleconsultation

Keywords: asthma copd emergency medical service teleconsultation telemedicine
evaluation of obstructive sleep apnea as a risk factor for pulmonary embolism

Conditions: Obstructive Sleep Apnea; Pulmonary Embolism

Summary: we evaluate the presence of osa in patients that have a computed tomography (ct) of the chest to rule out pulmonary embolism (pe) to determine if osa constitutes an independent risk factor for pe.


Eligibility criteria:
inclusion criteria: * male and female patients age 18 years and older with suspected pe

Keywords: obstructive sleep apnea pulmonary embolism male and female patients suspected of having a pulmonary embolism.
open label study of gsk2402968 in subjects with duchenne muscular dystrophy

Conditions: Muscular Dystrophies

Summary: the purpose of this study is to explore long-term safety, tolerability and efficacy of gsk2402968 in dmd subjects who previously participated in either dmd114117 or dmd114044.


Eligibility criteria:
inclusion criteria: * previous participation in either dmd114117 or dmd114044 * continued use of glucocorticoids * willing and able to comply with all protocol requirements * able to give informed consent * french subjects: eligible for inclusion only if either affiliated to or a beneficiary of a social security category. exclusion criteria: * subject experienced a serious adverse event or who met safety stopping criteria that remains unresolved from dmd114117 or dmd114044, which in opinion of the investigator could have been attributable to study medication and is ongoing, * use of anticoagulants, antithrombotics or antiplatelet agents, previous treatment with investigational drugs,except gsk2402968, within 1 month of the first administration of study medication, * current or anticipated participation in any investigational clinical studies, * history of significant medical disorder which may confound the interpretation of either efficacy or safety data e.g. current history of renal or liver disease/impairment, history of inflammatory disease.

Keywords: 968 duchenne dmd drisapersen
remote symptom monitoring on patient-reported outcomes with nudge strategies among patients with tumor in china

Conditions: Hepatocellular Carcinoma (HCC)

Summary: the goal of this clinical trial is to design a digital pro intervention model applicable to patients with hepatocellular carcinoma, and the main questions it aims to answer are: * can symptom management through patients' regular completion of the pro scale promote self-understanding, self-management and timely seeking of medical help, enable healthcare professionals to accurately and efficiently understand how patients really feel and respond in a timely manner, and ultimately improve health outcomes? * can digital interventions significantly improve outcomes such as symptom control and quality of life in cancer patients? researchers divided participants into an intervention group and a control group and compared them to see if digital interventions could improve patient health outcomes. participants will: * subjects in the intervention group will be asked to report symptom information weekly (7-day natural week, hereafter) via the public number, and the back office will give symptom management advice or issue alerts based on the filling. control subjects will not receive pro intervention. * participants can offer to withdraw from the study at any time.


Eligibility criteria:
inclusion criteria: 1. the patients are aged between 18 and 75 years old; 2. the patients have been diagnosed with locally advanced or metastatic liver cancer through pathological or imaging examinations; 3. the patients are currently receiving or have completed pd-1 monotherapy or pd-1 combination therapy; 4. the patients can participate in this study as per the requirements of the research protocol; 5. the patients voluntarily sign the informed consent form. exclusion criteria: 1. the patients have cognitive impairment or are unable to clearly identify their own symptoms and feelings; 2. the patients are illiterate or unable to understand the research content for other reasons; 3. the patients are currently participating in other clinical trials that may affect this study.
bone mass accrual in children with autism spectrum disorder

Conditions: Autism Spectrum Disorder; Bone Diseases, Developmental

Summary: this is a observational study to investigate the degree to which bone mineral density is impaired in boys with autism compared with typically developing controls.

studies have shown that bone cortical thickness is decreased in children with autism and other developmental disabilities. however it is not known whether bone mineral density (bmd) of these children is lower; neither is it known whether there is any correlation between bmd and the child's diet. the overall goal of this study is to improve the long term health of children and adolescents with autism spectrum disorder; more specifically the investigators aim to develop a pilot study to investigate the degree to which bmd is impaired in boys with autism and to explore specific additional risk factors. in addition, the aim is to investigate the degree to which bmd is impaired in boys with autism spectrum disorder (asd) and to explore specific contributing risk factors including nutritional analysis.

Eligibility criteria:
inclusion criteria: * boys 8-17 years chronological age * bmi between the 3rd and 97th percentiles * meets dsm-iv criteria for autism spectrum disorder (asd group) * scores \<15 on the social communication questionnaire (control group) exclusion criteria: * use of medications directly affecting bone metabolism including estrogen/ progesterone preparations and glucocorticoids except local application of glucocorticoid * use of anticonvulsants which affect bone density including diphenylhydantoin, phenobarbital, topiramate carbamazepine and valproic acid and also use of lithium * children with diseases known to affect bone mineral density including crohn's disease, celiac, thyroid and renal * children who will not tolerate lying still for 30 seconds

Keywords: bone mineral density autism spectrum disorder autism